Johnson & Johnson (JNJ)
7 Safe-Haven Stocks to Weather Any Storm
Investors often look to safe-haven equities for stability and reliable returns during uncertain economic times. Here are seven strong afe-haven stocks to buy that offer encouraging chances to endure financial disasters.
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Johnson & Johnson Stock
Johnson & Johnson's dividend currently yields more than 3%. The healthcare giant has increased its payout every year for more than half a century.
J&J-backed startup Rapport files for US IPO
Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
